Tiziana Life Sciences (TILS) – Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients August 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tuesday 4th August, 2020   Tiziana Life Sciences plc (“Tiziana” or the “Company”)  Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients   ·      Recently signed agreements with four contract research organizations (“CROs”) to initiate GMP manufacturing, develop inhalation technology, conduct inhalation safety toxicity study in monkeys, and initiate a human clinical trial in COVID-19 patients   This announcement contains inside information…

Continue reading